T-NeuroDx to present AlzheimerGuard human data at AAIC 2026

By AI, Created 7:46 PM UTC, June 04, 2026, /AGP/ – T-NeuroDx will share new human biomarker data on its AlzheimerGuard platform at the 2026 Alzheimer’s Association International Conference. The Albuquerque biotech says the findings could help improve early Alzheimer’s detection and trial enrichment as disease-modifying therapies advance.

Why it matters: - Alzheimer’s treatment development is increasing the need for diagnostics that can identify patients earlier and match them to clinical trials. - T-NeuroDx is positioning immune biomarkers as a blood-based tool for detecting Alzheimer’s disease and tracking progression. - The company says its work could help researchers and clinicians better understand who may benefit from intervention.

What happened: - T-NeuroDx said June 4, 2026, that it will present new data from its proprietary biomarker platform at AAIC 2026. - The presentation will appear in the Biomarkers category of the Emerging Topics Session. - The company is based in Albuquerque, New Mexico. - T-NeuroDx develops immune-based diagnostics for early detection of Alzheimer’s disease.

The details: - The AAIC presentation will highlight recent biomarker findings from human data. - T-NeuroDx says the data strengthen the case that adaptive immune responses can provide insight into disease status and progression. - The AlzheimerGuard platform is being developed as an accessible blood-based diagnostic solution. - The company says the platform is intended to support early intervention, improved clinical trials and better outcomes for patients at risk of Alzheimer’s disease. - T-NeuroDx continues to validate AlzheimerGuard through ongoing studies and collaborations. - Those efforts are aimed at expanding clinical datasets and demonstrating utility across diverse patient populations. - The company’s broader strategy centers on using immune-system biology to address unmet needs in neurodegenerative disease detection and management. - T-NeuroDx says the research builds on years of work studying age-related immune cell populations and their relationship to Alzheimer’s disease. - More information is available on T-NeuroDx on LinkedIn.

Between the lines: - The announcement signals a push to frame Alzheimer’s as both a neurodegenerative and immune-system disease. - If the biomarker approach holds up in broader studies, it could make screening and patient selection faster and less invasive than current pathways. - The focus on human data suggests T-NeuroDx is trying to move the platform closer to clinical relevance.

What’s next: - T-NeuroDx will present at AAIC 2026 and use the conference to advance validation of AlzheimerGuard. - The company expects ongoing studies and collaborations to add more clinical evidence across patient groups. - Further data will determine whether immune biomarkers can support wider use in early Alzheimer’s detection and trial enrichment.